Not easy but they chose to increase the shares authorized to increase the shares that can be issued for a deal. They could also have done a 1 for X reverse split with no change in the shares authorized (e.g. URMD 15M/100M to 500K/100M). The increase is "big" but it is relative and the share oustanding is "low." PPXP was 3M/100M. Potential shares go to 290M whether or not they will be all issued?
At least they are thinking about a deal and getting ready for one which is encouraging news for this shell with a nice pop today as a result.
Also interesting is that the amendment was filed on Wednesday and Tuesday was 52W low at 0.052! And November had a one day 52W high of 0.15 on 16X volume!...
One other way is to do a 1 for X reverse split with no change in the number of shares authorized e.g. URMD to go from about 15M/100M to 500K/100M so potential shares go from 85M to
The number of shares authorized might seem high but it is all relative and depends on the deal being worked on. For reference PPXP was 3M/100M
At least they are thinking about a deal and getting ready for one which is encouraging news for this shell with a nice pop today as a result.
Also interesting is that the amendment was filed on Wednesday and Tuesday was 52W low at 0.052! And November had a one day 52W high of 0.15 on 16X volume!...
One other way is to do a 1 for X reverse split with no change in the number of shares authorized e.g. URMD to go from about 15M/100M to 500K/100M so potential shares go from 85M to
The number of shares authorized might seem high but it is all relative and depends on the deal being worked on. For reference PPXP was 3M/100M
Recent BCDA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 10:14:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 12:00:10 PM
- BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency • GlobeNewswire Inc. • 05/21/2026 12:00:00 PM
- BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase • GlobeNewswire Inc. • 05/19/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 12:20:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 09:46:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 12:05:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 12:05:55 PM
- BioCardia Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/15/2026 12:00:00 PM
- BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 • GlobeNewswire Inc. • 05/11/2026 09:10:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:00:09 PM
- BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways • GlobeNewswire Inc. • 05/08/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:00:08 PM
- BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures • GlobeNewswire Inc. • 04/28/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:04:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 12:00:09 PM
- BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 08:30:15 PM
- BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure • GlobeNewswire Inc. • 04/02/2026 02:11:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:00:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:05:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 08:31:26 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/24/2026 08:30:33 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/24/2026 08:05:25 PM
- BioCardia Reports 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM


